Dergiler / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 7

Usefulness of argon plasma coagulation for superficial esophageal squamous-cell neoplasia in patients at high risk or with limited endoscopic resectability

Sayfa
529–537
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The 3-year overall survival rate was 87.0%, and the 3-year recurrence-free survival rate was 97.2%.Conclusion: APC can be a useful treatment option for SESCN in patients with a limited life expectancy, poor performance status, or technical difficulty in resection of superficial neoplasms.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Endoscopic resection is the standard treatment for superficial esophageal squamous-cell neoplasia (SESCN).
📊
Temel Bulgular & Veri:We retrospectively studied the usefulness of argon plasma coagulation (APC) in patients with SESCN.Materials and Methods: The study comprised 45 patients with SESCN (81 lesions) who underwent APC in our hospital from March 1999 to August 2016.
💡
Sonuç & Katkı:The 3-year overall survival rate was 87.0%, and the 3-year recurrence-free survival rate was 97.2%.Conclusion: APC can be a useful treatment option for SESCN in patients with a limited life expectancy, poor performance status, or technical difficulty in resection of superficial neoplasms.
🔬Tür:Araştırma Makalesi
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Endoscopic resection is the standard treatment for superficial esophageal squamous-cell neoplasia (SESCN). However, we encounter patients in whom endoscopic resection is difficult to perform. We retrospectively studied the usefulness of argon plasma coagulation (APC) in patients with SESCN.Materials and Methods: The study comprised 45 patients with SESCN (81 lesions) who underwent APC in our hospital from March 1999 to August 2016. Clinicopathological characteristics, treatment time, the presence or absence of metastasis and recurrence, adverse events, and outcomes were studied.Results: The median follow-up was 40 months. The median age was 70 years. The tumor diameter was 10 mm or longer in 48 lesions and less than 10 mm in 33 lesions. The median treatment time was 22 minutes. The reasons for selecting APC were as follows: technical difficulty caused by the presence of metachronous multiple lesions in the radiation field after chemoradiotherapy or close proximity to the ulcer scar remaining after endoscopic treatment in 49 lesions (60.4%), and the presence of underlying diseases in 26 lesions (32.0%). Adverse events occurred in 2 patients (4.4%) who had hypoxemia due to over-sedation. Two lesions (2.5%) recurred locally but could be controlled by additional APC. No patient had metastasis or recurrence or died of esophageal neoplasia. The 3-year overall survival rate was 87.0%, and the 3-year recurrence-free survival rate was 97.2%.Conclusion: APC can be a useful treatment option for SESCN in patients with a limited life expectancy, poor performance status, or technical difficulty in resection of superficial neoplasms.

🔖

Bu Makaleye Atıf Yap

KUBOTA, Y., TANABE, S., ISHİDO, K., YANO, T., WADA, T., WATANABE, A., AZUMA, M., KATADA, C., KOİZUMİ, W. (2020). Usefulness of argon plasma coagulation for superficial esophageal squamous-cell neoplasia in patients at high risk or with limited endoscopic resectability. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 7, 529–537. https://ajindex.com/articles/409224

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. The Japan Esophageal Society. Guidelines for diagnosis and treatment of carcinoma of the esophagus 2017. Tokyo: Kanehara Co Ltd
  2. Muto M, Minashi K, Yano T, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol 2010; 28: 1566-72. [Crossref] 3. Yoshida T, Inoue H, Usui S, Satodate H, Fukami N, Kudo SE. Narrow-band imaging system with magnifying endoscopy for superficial esophageal lesions. Gastrointest Endosc 2004; 59: 288-95. [Crossref] 4. Grund KE, Storek D, Farin G. Endoscopic argon plasma coagulation first clinical experiences in flexible endoscopy. Endosc Surg Allied Technol 1994; 2: 42-6
  3. Grade AJ, Shah IA, Medlin SM, Ramirez FC. The efficacy and safety of argon plasma coagulation therapy in Barrett’s esophagus. Gastrointest Endosc 1999; 50: 18-22. [Crossref] 6. Sagawa T, Takayama T, Oku T, et al. Argon plasma coagulation for successful treatment of early gastric cancer with intramucosal invasion. Gut 2003; 52: 334-9. [Crossref] 7. Kitamura T, Tanabe S, Koizumi W, Mitomi H, Saigenji K. Argon plasma coagulation for early gastric cancer: technique and outcome. Gastrointest Endosc 2006; 63: 48-54. [Crossref] 8. Tahara K, Tanabe S, Ishido K, et al. Argon plasma coagulation for superficial Esophageal squamous-cell carcinoma in high-risk patients. World J Gastroenterol 2012; 18: 5412- 7. [Crossref] 9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83. [Crossref] 10. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) ver 4.0. http://evs.nci.nih.gov/ftp1/ CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 30 January 2018
  4. Oyama T, Inoue H, Arima M, et al. Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology: magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 2017; 14: 105-12. [Crossref] 12. Fujimoto K, Fujishiro M, Kato M, et al. Japan Gastroenterological Endoscopy Society Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014; 26: 1-14. [Crossref] 13. Koike Y, Hirasawa D, Fujita N, et al. Usefulness of the thread-traction method in esophageal endoscopic submucosal dissection: randomized controlled trial. Dig Endosc 2